

# US PATIENT & ONCOLOGIST AWARENESS, USAGE, & ATTITUDES TOWARD WHOLE PERSON INTEGRATIVE ONCOLOGY

FINAL REPORT: SEPTEMBER 30, 2022 (UPDATE OCT 7)
PREPARED FOR SAMUELI FOUNDATION
BY IQVIA

### TABLE OF CONTENTS

### **Contents**

- Methodology
- Executive Summary
- Detailed Findings
  - Patient Supplemental
  - Oncologist Supplemental
  - By Urban/Suburban/Rural (Patients and Oncologists)
  - By Age (Patients and Oncologists)
  - By Patient Fact-G7 Score
  - By Patient User/Non-User of Complementary
  - By Patient Ethnicity
  - By Oncologist Gender
  - By Oncologist Region
- Appendix

### **METHODOLOGY**


### **METHODOLOGY OVERVIEW**

	© Oncologists	Reports Patients
Survey Length	15 minutes	15 minutes
Sample Frame	US-based Oncologists treating any type of cancer	People in the US diagnosed with any type of cancer within the past two years
Size	152 representative Oncologists	1,004 representative cancer patients
	Soft quotas and RIM weighting were used to balance for those that specialize in solid tumors (65%) vs. hematology (35%), as well as age, location (urban/suburban/rural), and US region	Soft quotas and RIM weighting were used to balance on gender, age, ethnicity, location (urban/suburban/rural), and US region
Data Cuts Explored	<ul> <li>Practice location – urban/suburban/rural</li> <li>Gender</li> <li>Region</li> <li>Age in years – 3 categories (&lt;40, 41-63, 64+)</li> </ul>	<ul> <li>Living location – urban/suburban/rural</li> <li>Ethnicity – Caucasian, African American, Hispanic, other</li> <li>Complementary therapy – User/Non-User (during treatment)</li> <li>Age – 4 categories (18-50, 51-65, 66-75, 76+)</li> </ul>
Fieldwork Dates	August 12-September 1, 2022	August 12-September 1, 2022

- All data in the report are weighted to represent the population; however, base sizes are reported as unweighted to accurately represent the survey data
- Significant differences at 95% C.I. are noted on slides throughout the report wherever applicable and/or notable among cuts like Location, Ethnicity, Age of Patients and ONCs, Fact-G7 Scores, Gender and Region of ONCs as:
  - Urban (U) vs. Suburban (S) vs. Rural (R) Caucasian / White (C) vs. African American / Black (A) vs. Hispanic / Latino (H) vs. Others (O) 18-50 (A) vs. 51-65 (B) vs. 66-75 (C) vs. 75+ (D) <=40 (A) vs. 41-63 (B) vs. 64+ (C) High Fact- G7 Score (H) vs. Medium Fact-G7 Score (M) vs. Low fact-G7 Score (L) User (U) vs. Non-Users (N) Male (M) vs. Female (F) Northeast (N) vs. Midwest (M) vs. South (S) vs. West (W)



### PATIENT DEMOGRAPHICS (1/2)



See Appendix for additional demographics



### PATIENT DEMOGRAPHICS (2/2)


Solid tumors that skew younger:

- **Breast (18-65)**
- **Cervical (18-50)**
- Testicular (18-50)
- Thyroid (18-50)

Solid tumors that skew older:


- Bladder (66+)
- Melanoma (51+)
- insufficient sample size to Prostate (66+) draw age conclusions

**Liquid tumors have** 





### ONC DEMOGRAPHICS (1/2)



<sup>\*</sup>Others includes Some other ethnic background


ONC - S1, S3, S6, Q20, Q21, Q22


Data Labels ≥ 4% are shown

<sup>\*\*</sup>Other Oncology includes Gynecological Oncology, Radiation Oncology, Surgical Oncology



### **ONC DEMOGRAPHICS (2/2)**







Data Labels ≥ 4% are shown ONC- S2, S4, S5, S8, S10, Q23

### **Executive Summary**

### **EXECUTIVE SUMMARY – TOTAL SAMPLE (1/2)**





### WHILE THERE IS STRONG BELIEF IN INTEGRATIVE ONCOLOGY ACROSS >50% OF CANCER PATIENTS & ONCOLOGISTS, MORE CONVERSATIONS ARE NEEDED EARLIER IN THE TREATMENT PROCESS, ALONG WITH MORE ACCESS TO TOP THERAPIES

### **Strong Belief in Integrative Oncology Benefits**

- More than 50% of people with cancer and 60% of treating ONCs strongly agree on the benefits of integrative oncology – both during and after treatment – to manage SE and improve overall well-being
- Additionally, over **40%** of both groups believe the integrative approach improves treatment outcomes (patients) and overall survival (ONCs)

### **ONC-Patient Conversations Needed Sooner and More** Consistently

- Patients and ONCs agree that the integrative conversation happens only for ~40% of cancer patients, despite patient interest in numerous complementary therapies
- **62%** of cancer patients desire the first integrative conversation before starting treatment, with majority of the remainder wanting it within 1 month of treatment start

### **Top Therapies of Interest** are Not Always Widely **Available**

- Across 12 complementary therapies studied, **66%** of patients report using at least one as part of their treatment, with ~1 in 3 using Nutrition Consultation followed by Mental Health Support
- While **84%** of institutions offer at least one complementary therapy, patients want more *Massage Therapy*, Exercise Consultation, and Meditation/Mindfulness – offered by <50% of institutions

# EXECUTIVE SUMMARY – TOTAL SAMPLE (2/2) ONCOLOGISTS AND PATIENTS ALIKE WANT TO LEARN MORE ABOUT INTEGRATIVE ONCOLOGY, BUT FACE BARRIERS OF EDUCATION, ACCESS, AND IMPLEMENTATION





## ONCs Desire to Learn More, but Face Implementation Barriers

- 76% of ONCs are interested in learning more about the evidence base for integrative oncology this lack
  of knowledge is a barrier to adoption for ~one-third of ONCs
- ONCs single biggest barrier is lack of insurance reimbursement (49%); other top barriers are lack of staff to implement (39%), no time to fit into conversations (31%) and a misperception that patients are not interested (32%)

### Patients Also Desire to Learn More, but Face Education and Access Barriers

- Satisfaction with the treatment experience would increase for 35% of cancer patients if their healthcare team had offered more complementary therapies
- At 26% each, patients top two barriers to complementary adoption are lack of knowledge and treating institution not offering as an option


### OOP Cost of Complementary Also a Barrier, but Nominal Fees May Be Manageable

- 23% of cancer patients report not having the money to pay for complementary therapies as a barrier
- In a price-sensitivity exercise, the range patients are willing to pay is \$11-\$25 monthly











<sup>\*5%</sup> or less each of ONCs and patients had strong disagreement (1 or 2 on 7-point scale) with each statement












**Mindfulness** 










### **Supplemental Data**

66% of patients report using at least one complementary therapy as part of their treatment but ONCs perceive only 40% of patients use the integrative approach



## Patients and ONCs agree that the integrative conversation happens only for ~40% of cancer patients; however, 76% of ONCs are interested in additional data on the benefits







% of cancer patients who discussed integrative treatments with their ONCs






**42%** 



% of cancer patients ONCs actively suggested a complementary therapy

% ONCs desire to learn more about integrative treatments evidence base




In demographic analysis:

- Urban and suburban ONCs are directionally higher than rural ONCs on wanting to learn more
- ONCs desire to learn more is stronger the younger they are
- ONCs in the West and Midwest are most interested




## Compared to ONCs, patients are saying they would like the timing of the first integrative discussion to be <u>earlier</u> in the treatment plan (before starting treatment)












Other ONC top barriers include realworld and logistic issues: lack of insurance coverage and limited time/staff/space to discuss and deliver complementary therapies

It follows that 59% of ONCs report some work needs to be done before their institution is ready to offer more


Readiness of the Institute to Deliver the Complementary Therapies



- Yes, fully ready
- Yes, but some additional work needs to be done first
- No, not ready




# Not knowing enough about complementary therapies and hospital did not offer complementary therapies are the two largest patient barriers to further adoption – slightly more so than not having the money to pay OOP






## While two-thirds of patients currently do not pay OOP for complementary therapies, there is willingness to pay in the range of \$11-\$25 monthly for their top therapies



### 70% of patients report extreme satisfaction with their cancer treatment experience; however, 35% would increase satisfaction if they were offered more complementary therapies



# EXECUTIVE SUMMARY – URBAN/SUBURBAN/RURAL: WHILE URBAN PATIENTS ARE MORE POSITIVE ABOUT AND USE MORE INTEGRATIVE, ONCS ACROSS LOCATIONS HAVE SIMILAR LEVELS OF AWARENESS & BARRIERS – THOUGH FOUR OF THE KEY MODALITIES ARE OFFERED MORE IN URBAN AREAS





- Many more ONCs practice in urban areas (48%) than rural (10%) yet over 20% of cancer patients live in rural areas
  - Suburbs are heavily represented by both groups: 52% of patients and 42% of ONCs are located in the suburbs
  - Based on patient self-reported data, rural have more of a Medicare population (53%) vs. urban and suburban having ~40% each of private and Medicare
- Urban-dwelling patients have stark differences compared to those in other locations urban have higher interest in and use
  of complementary therapies, more positive attitudes about integrative oncology, and are more likely to have discussed
  integrative with their ONC
  - Urban cancer patients also skew younger and more have private insurance, which may in part explain the differences
- Access to complementary therapies does appear better in urban locations; ONCs report four top modalities offered
  significantly more in urban than other locations: mental health, exercise consultation, patient support groups, and spiritual
  services
  - ONCs in suburban settings refer patients out for complementary services more than urban, who are more likely to offer the services onsite
  - Questions still remain about the execution and how financially accessible these modalities are to patients
- ONC awareness of complementary therapies and barriers to increased integrative adoption are mostly consistent across the locations
  - Two barrier exceptions: suburban and rural ONCs report barrier of not having other physician buy-in and patients confusing complementary with palliative or hospice care
  - Top patient barriers are similar across locations, with urban patients significantly more concerned about insurance not covering

# EXECUTIVE SUMMARY – PATIENT FACT-G7 AND USER/NON-USER: COMPLEMENTARY USERS AND THOSE WITH HIGH FACT-G7 SCORES ARE MORE INVESTED IN INTEGRATIVE ONCOLOGY THAN NON-USERS AND PATIENTS WITH LOWER SCORES, BUT STILL FACE BARRIERS OF ACCESS AND FUNDING



- Across all 12 modalities, higher FACT-G7 patients use significantly more complementary therapies than those with medium and low FACT-G7 scores
  - High FACT-G7 and complementary users are also willing to pay more than those with lower scores or non-users
- Among low FACT-G7 score patients and complementary non-users, there is a need to understand the benefits of complementary therapies
- With higher FACT-G7 (med and high scores) and complementary users, they are attitudinally significantly more "bought in" than the low FACT-G7 and non-users
  - The higher scoring and complementary users therefore face other barriers like not knowing where to access complementary and inability to pay OOP/insurance not covering
- Low FACT-G7 and non-users are also heavily skewed toward Medicare, where other groups are more balanced between private insurance and Medicare

### **CONCLUSIONS**



### INTEGRATIVE ONCOLOGY EDUCATION TO ONCOLOGISTS AND PATIENTS CAN LEVERAGE MISPERCEIVED BARRIERS, POSITIVE USER ATTITUDES, AND URBAN HOSPITALS AS A MODEL FOR LEADING IN PATIENT ENGAGEMENT




Education to Oncologists should address patient barriers and ONC misperceptions	<ul> <li>Despite 32% of ONCs reporting patients are not interested in complementary therapies, one-third or more of patients are strongly interested in each of Nutrition, Massage, Exercise, and Mental Health Support</li> <li>At 26% each, the biggest patient barriers to further integrative oncology adoption are not knowing enough and their hospital not offering complementary therapies as an option</li> </ul>
Clear and simple messages about how integrative oncology relates to improved patient outcomes are also needed for Oncologists	<ul> <li>76% of Oncologists also want to learn more about the integrative treatment evidence base, driven by younger ONCs and those in urban areas</li> <li>Among the 24% who do not want to learn more about integrative, they say there is not enough clinical evidence</li> </ul>
Hospitals from Urban settings that offer integrative modalities can be used as examples of ways to increase patient engagement	<ul> <li>Patients in Urban settings are exposed to more integrative oncology – specifically Mental Health, Exercise, Patient Support Groups, and Spiritual Services, four of the top six most-used therapies</li> <li>Urban-dwelling patients also have higher interest in and use of complementary therapies, more positive attitudes about integrative oncology, and are more likely to have discussed integrative with their ONC</li> </ul>
Patient education can focus on improvements in quality of life among those that use complementary therapies	<ul> <li>Patients with higher FACT-G7 scores have used complementary therapies significantly more than patients with medium and low FACT-G7 scores</li> <li>Users also strongly believe that complementary therapies are helping to manage treatment side effects, improve overall well-being, and improve their survival</li> </ul>
Both groups should be encouraged to start a patient-physician dialog about integrative oncology near the time of starting treatment	<ul> <li>That conversation only happens for ~40% of cancer patients currently, and it is previously documented that the recommendation from healthcare team strongly influences complementary use</li> <li>Majority of cancer patients want to have the integrative conversation before starting treatment; within 1 month of starting treatment is sufficient for majority of ONCs</li> </ul>

## **DETAILED FINDINGS Patient Supplemental**




## If patients were able to go back in time, 40% would have chosen a hospital that offered a greater number of complementary therapies





## Price Sensitivity Meter: to maximize patient involvement, \$25/month is the higher end of what patients are willing to pay for access to their top 1-5 complementary therapies



### **Findings**


- Minimal Price

   (Intersection of Too cheap and Expensive):
   \$11
- Optimal Price

   (Intersection of Too cheap and Too
   Expensive): \$14
- Maximum Price (Intersection of Good Value and Too Expensive): \$25



## ~30% of patients are very likely to purchase a package that includes their top 1-5 complementary therapies for \$50/month




#### \*Methodology Note:

Likelihood to purchase analysis is based on the Juster Purchase Intent scale. Juster assigns a probability to of purchase to each response. At \$50 cost, the price points for each probability are:

No Chance-\$0.5 Very slight-\$5 Slight-\$10 Some-\$15 Fair-\$20 Fairly good-\$25 Good-\$30 Probable-\$35 Very probable-\$40 Almost Sure-\$45 Certain-\$49.5



## From physical health to mental health, majority of patients express positivity when evaluating their overall well-being



#### **Supplemental Data**


49% of patients currently undergoing active treatment for cancer







### Patient responses to FACT-G7 metrics are well-distributed, except for having nausea which majority do not experience




The share for total FACT-G7 scoring depicting the QoL for patients is as follows:

Low (score 0-12): 23% Med (score 13-20): 47% High (score 21-28): 30%

## **DETAILED FINDINGS Oncologist Supplemental**




## 70% or more of ONCs are moderately to very aware of the top 10 complementary therapies, with *Nutrition*, *Mental Health*, and *Patient Support Groups* leading the way



ONC-Q1 Data Labels ≥ 4% are shown



### When a complementary therapy is offered by an institution, it is most often offered onsite



Among the top modalities available, exercise is most often offered at a different location (29%)

32



## Roughly one-third of ONCs suggest philanthropic efforts when considering how to lower complementary therapy OOP costs for patients

· · · · · · · · · · · · · · · · · · ·	t or Creative Solutions to lower OOP costs of respondents, n=152)		
Base: Total ONCs		"Discussing ways to <b>offer low-cost services</b> at	
Group Offering Services/Donated Funds/NGO/Philanthropic organization	31%	facilities that are willing to help cancer pts place ads for volunteers' donations or charities that might help cover costs"	
Hospital/Manufacturers subsidized	12%		
Patients have to pay out of pocket	9%		
Education and time	7%	"Establish a <b>VOLUNTARY non-profit</b> toward which patients may send contribution, set a <b>FUND ME</b>	
Nutrition/Mental Health/Exercise support	2%	<pre>program, run races/marathons to contribute for     such support"</pre>	
Benefits of the therapy	2%		
Not sure/No solution/None	36%		

"Referring patients to **community resources** that offer complementary services pro bono or at greatly **reduced/subsidized rate**"

"We have a local foundation that offers free exercise classes to cancer patients in the community. The foundation is supported by donations, and the donations can come at any time but there are also fundraisers that assist in the donations."

**DETAILED FINDINGS**By Urban/Suburban/Rural (Patient and Oncologist)

### **SUMMARY – URBAN/SUBURBAN/RURAL:**

### Patients


# WHILE URBAN PATIENTS ARE MORE POSITIVE ABOUT AND USE MORE INTEGRATIVE, ONCS ACROSS LOCATIONS HAVE SIMILAR LEVELS OF AWARENESS & BARRIERS – THOUGH FOUR OF THE KEY MODALITIES ARE OFFERED MORE IN URBAN AREAS



- Many more ONCs practice in urban areas (48%) than rural (10%) yet over 20% of cancer patients live in rural areas
  - Suburbs are heavily represented by both groups: 52% of patients and 42% of ONCs are located in the suburbs
  - Based on patient self-reported data, rural have more of a Medicare population (53%) vs. urban and suburban having ~40% each of private and Medicare
- Urban-dwelling patients have stark differences compared to those in other locations urban have higher interest in and use
  of complementary therapies, more positive attitudes about integrative oncology, and are more likely to have discussed
  integrative with their ONC
  - Urban cancer patients also skew younger and more have private insurance, which may in part explain the differences
- Access to complementary therapies does appear better in urban locations; ONCs report four top modalities offered
  significantly more in urban than other locations: mental health, exercise consultation, patient support groups, and spiritual
  services
  - ONCs in suburban settings refer patients out for complementary services more than urban, who are more likely to offer the services onsite
  - Questions still remain about the execution and how financially accessible these modalities are to patients
- ONC awareness of complementary therapies and barriers to increased integrative adoption are mostly consistent across the locations
  - Two barrier exceptions: suburban and rural ONCs report barrier of not having other physician buy-in and patients confusing complementary with palliative or hospice care
  - Top patient barriers are similar across locations, with urban patients significantly more concerned about insurance not covering



## Directionally, rural-based ONCs are slightly less enthusiastic about integrative oncology than those based in other locations, other than for SE management




### **Supplemental Data**

- Related, awareness of complementary therapies is mostly consistent across the ONC location groups
- Mental health and patient support groups are the only ones where urban ONCs are significantly more aware



# Patients living in an urban setting have significantly more positive views of integrative oncology than those in suburban and rural settings




### **Supplemental Data**

There are also some demographic differences that may relate to attitudes:

- Urban are most likely to have a postgraduate degree
- Urban has a younger cohort (22% ages 45-54), while suburban and rural each have 65% ages 65 or older
- Urban skew to private insurance, where suburban and rural are majority Medicare



## Urban patients report a significantly higher interest in and willingness to pay for complementary therapies than those in other locations



\*T2B = top 2 box = selection of 6 or 7 on 7-point scale

## **Supplemental Data**

Average current spend per month for complementary therapies:

> **Urban**: \$54<sup>S,R</sup> Suburban: \$21 **Rural**: \$24


### **Supplemental Data**

Patients located at **Urban** regions are willing to pay the highest amount for a monthly package deal at an average price (Juster Purchase Intent Scale^) of **\$26.30** 









## **Supplemental Data**

Interestingly, ONCs report a similar level of availability for most complementary services regardless of location; however, the four highlighted are offered significantly more in urban than other locations

#### **Supplemental Data**

% of cancer patients who discussed integrative treatments with their ONCs:

> Urban: 52% S,R Suburban: 30%


> > **Rural**: 36%

# oan and



# Urban ONCs tend to want to have the integrative discussion sooner, where suburban and rural are more willing to wait up to a month post-starting treatment





## **Supplemental Data**

Majority of patients also want to have the discussion before starting treatment, with suburban and rural even stronger than urban:


After my diagnosis, but before I started treatment:

> Urban: 52% Suburban: 65%<sup>U</sup>

Rural: 68%<sup>U</sup>



# Urban ONCs have a high desire to learn more about integrative evidence base; however, nearly 25% of them say their institution is not ready to deliver more



#### **Supplemental Data**

% of cancer patients who discussed integrative treatments with their ONCs:


Urban: 44% Suburban: 43% Rural: 31%

% of cancer patients using at least one complementary therapy

> Urban: 40% Suburban: 41% Rural: 36%




# Though there are not significant differences in barriers based on physician location, more rural ONCs report barriers overall





# The top patient barriers are mostly consistent across locations; urban report insurance issues more than others while suburban highlight not having funds



**DETAILED FINDINGS By Age (Patient and Oncologist)** 

## **SUMMARY – AGE:**








- A higher proportion of (younger) patients ages 18-50 has strong beliefs about the benefits of integrative oncology
  - More patients in this age group also report discussing complementary therapies with their ONC and usage across all
     12 modalities
  - Patients ages 18-50 also currently spend more and are willing to pay more for complementary therapies than all other ages
  - Younger patients are also the most educated and skew toward private insurance
- Barriers to further adoption are different based on the patient age
  - The youngest group (ages 18-50) faces insurance approval barriers, are too sick or weak from the cancer treatment, and say their ONC is not supportive
  - The single biggest barrier for ages 51-65 is not having enough money for complementary therapies, which may be related to approaching retirement age
  - The two oldest groups (ages 66+) do not know enough about complementary and are more focused on getting through their medical treatment
- ONCs report similar barriers to integrative use across age groups, but they have some attitudinal differences
  - Directionally, more younger ONCs (age 40 or younger) support the use of complementary therapies compared to 41–63-year-old ONCs
  - Younger ONCs are most likely to discuss integrative treatments and suggest a complementary therapy to their patients, as well as be aware of patients' usage
  - Younger ONCs are more eager to learn about the evidence base for integrative oncology; compared to older ONCs, they also believe that their institution is ready to deliver complementary therapies




# Directionally, more younger ONCs support the use of complementary therapies compared to 41-63 year old ONCs






# Younger patients believe that complementary therapies are effective in helping manage cancer side effects and are most supportive of integrative in general





# Similarly, younger patients are more interested in using complementary therapies as part of their cancer treatment compared to older patients




### **Supplemental Data**

## **Younger Patients (18-50)** are the most educated and skewed toward private insurance; they are willing to pay the highest amount for a monthly package deal at an average price (Juster Purchase Intent Scale^) of \$33.4



# Significantly more 18–50-year-old patients report using a vast array of complementary therapies compared to the older subgroups of patients



## **Supplemental Data**

% of cancer patients who discussed integrative treatments with their ONCs:

**18-50**: 77% B,C,D

**51-65**: 44%<sup>C,D</sup>

**66-75**: 25%<sup>D</sup>

**75+**: 16%

#### **Supplemental Data**

Average spend per month for the therapies:

**18-50:** \$97 B,C,D


**51-65:** \$32 <sup>C,D</sup>

**66-75:** \$14 <sup>D</sup>

**75+:** \$6

## Similar to their interest in complementary therapies, younger patients would have been **Patients** more likely to choose a hospital that offered more complementary therapies if they were





able to go back in time




# Younger ONCs are most likely to discuss integrative treatments and suggest a complementary therapy to their patients, as well as be aware of patients using at least one complementary therapy

	<=40 [A] (n=38)	41-63 [B] (n=98)	64+ [C] (n=16)
% of cancer patients who discussed integrative treatments with their ONCs	<b>52%</b> <sup>B</sup>	40%	43%
% of cancer patients ONCs actively suggested a complementary therapy	<b>59</b> % <sup>B</sup>	45%	44%
% of cancer patients using at lease one complementary therapy	<b>49</b> % <sup>°</sup>	41%	31%




# While older and younger ONCs believe the integrative conversation should happen before starting treatment, 41-63 year old ONCs are more split on the timing






# Younger ONCs are more eager to learn about the evidence base for integrative oncology; compared to older ONCs, they also believe that their institution is ready to deliver complementary therapies






# ONCs report similar barriers regardless of age, though ONCs 40 or younger may be more aware of the clinical evidence for complementray use





Though younger patients are eager to learn more about complementary therapies, they report cost / access, feeling too weak from cancer treatment, and non-supportive oncologists as the main barriers to further adoption



# **DETAILED FINDINGS By Patient FACT-G7 Score**


# SUMMARY – PATIENT FACT-G7 AND USER/NON-USER: COMPLEMENTARY USERS AND THOSE WITH HIGH FACT-G7 SCORES ARE MORE INVESTED IN INTEGRATIVE ONCOLOGY THAN NON-USERS AND PATIENTS WITH LOWER SCORES, BUT STILL FACE BARRIERS OF ACCESS AND FUNDING



- Across all 12 modalities, higher FACT-G7 patients use significantly more complementary therapies than those with medium and low FACT-G7 scores
  - High FACT-G7 and complementary users are also willing to pay more than those with lower scores or non-users
- Among low FACT-G7 score patients and complementary non-users, there is a need to understand the benefits of complementary therapies
- With higher FACT-G7 (med and high scores) and complementary users, they are attitudinally significantly more "bought in" than the low FACT-G7 and non-users
  - The higher scoring and complementary users therefore face other barriers like not knowing where to access complementary and inability to pay OOP/insurance not covering
- Low FACT-G7 and non-users are also heavily skewed toward Medicare, where other groups are more balanced between private insurance and Medicare




# High Fact-G7 Score patients have a stronger belief in an integrative treatment approach compared to Medium and Low Fact G7-Score patients





# Like complementary Users, High Fact-G7 Score patients show an increased level of interest towards complementary therapies compared to Medium & Low Fact-G7 patients



#### **Supplemental Data**

**High Fact G7-Score** are willing to pay the highest amount for a monthly package deal at an average price (Juster Purchase Intent Scale^) of \$28.5


## **Supplemental Data**

**Low group** is heavily Medicare and medium group is also nearly half Medicare

High group is much more balanced to private and Medicare



# High Fact-G7 Score patients are also more likely to use complementary therapies compared to Medium and Low Fact-G7 Score patients



## **Supplemental Data**


Average spend per month for the therapies:

High Fact-G7 Score: \$57<sup>M,L</sup>
Medium Fact-G7 Score: \$34<sup>L</sup>

Low Fact-G7 Score: \$10




Similar to their usage of complementary therapies, High Fact-G7 Score patients would have been more likely to choose a hospital that offered more complementary therapies if they were able to go back in time






# Low Fact-G7 Score patients report not having interest, low awareness and being focused on getting through their medical treatments as the main barriers for adoption of complementary therapies



**DETAILED FINDINGS**By Patient User/Non-User of Complementary




# Not surprisingly, users are far more receptive towards Integrative Oncology compared to non-users





## Users are likely to spend more money on complementary therapies compared to nonusers; with their ideal monthly package being ~\$27/month



## **Supplemental Data**

Average spend per month for the therapies:


> Users: \$50<sup>N</sup> Non-Users: \$2

## **Supplemental Data**

**Users** are willing to pay the highest amount for a monthly package deal at an average price (Juster Purchase Intent Scale^) of \$27.1




# Users are split between staying with a hospital that offers the same amount of complementary they were exposed to versus going to a hospital that offers more






# The top barriers are similar across patient user groups; however, non-users especially would benefit from education about the benefits of integrative oncology





## Significantly more non-users report having Medicare compared to Users




# **DETAILED FINDINGS By Patient Ethnicity**

Data for the various ethnic groups should be interpreted with caution. Younger patients (age 40-64) are over-represented in the Hispanic sample, and to a lesser extent in the Black and Other Ethnicity samples. Therefore, these individual ethnic samples are not representative of the age distribution within the ethnic population.

Data for the Caucasian/White sample is not affected.



It appears that Hispanic and Black patients are significantly more receptive to an integrative treatment approach, however this is likely driven by a sample bias of much younger patients in the Hispanic cohort, and to lesser extent, the Black cohort



#### Methodology Note

Data for Hispanic patients (and to lesser extent, Black and Other) is skewed to a bias in the younger age groups, so interpret with caution.


#### Age 40-64:

White: 30% Black: 58% Hispanic: 73% Asian/Pacific: 61% Am. Indian/Aleut: 64%

70



# Hispanic patients report a significantly higher interest and are willing to pay more for complementary therapies at a rate of about \$35; however, the Hispanic sample skews very young which could in part explain the differences



#### **Supplemental Data**

Similar to this trend. **Hispanics** are willing to pay the highest amount for a monthly package deal at an average price (Juster Purchase Intent Scale^) of **\$35.10** 

## **Methodology Note**

Data for Hispanic patients (and to lesser extent, Black and Other) is skewed to a bias in younger age groups, interpret w/caution.

#### Age 40-64:


White: 30% Black: 58% Hispanic: 73% Asian/Pacific: 61%

Am. Indian/Aleut: 64%

^The price point for each probable-\$35, Very probable-\$40, Almost Sure-\$45, Certain-\$49.5 Alight-\$10, Some-\$15, Fair-\$20, Fairly good-\$25, Good-\$30, Probable-\$35, Very probable-\$40, Almost Sure-\$45, Certain-\$49.5 \*Others = Asian or Pacific Islander + Native American, Eskimo, or Aleut + Other Ethnicity [C, A, H, O] denote statistical differences between different types of Ethnicities at 95% C.L.



# Similarly, Hispanic patients report a greater usage of complementary therapies compared to the other groups; however, this is likely driven by a sample bias of much younger patients in the Hispanic cohort



### **Supplemental Data**

Average spend per month for the therapies:

Caucasian: \$25
African American /
Black: \$31

Hispanic / Latino: \$82

**Others:** \$36

### **Methodology Note**

Data for Hispanic patients (and to lesser extent, Black and Other) is skewed to a bias in younger age groups, interpret w/caution.

#### Age 40-64:


White: 30% Black: 58%

Hispanic: 73%

Asian/Pacific: 61% Am. Indian/Aleut: 64%



Each of the ethnic groups are split between choosing a hospital that offers more complementary therapies versus a similar number of therapies, with Hispanic patients showing an inclination toward more (however, Hispanic sample is skewed very young)



#### **Methodology Note**

Data for Hispanic patients (and to lesser extent, Black and Other) is skewed to a bias in younger age groups, interpret w/caution.


#### Age 40-64:

White: 30%
Black: 58%
Hispanic: 73%
Asian/Pacific: 61%

Am. Indian/Aleut: 64%




Hispanic patients report insurance and lack of support at hospital as the main barriers, while White patients report lack of knowledge and money along with support at hospital as the main barriers for adoption of complementary therapies



\*Others = Asian or Pacific Islander + Native American, Eskimo, or Aleut + Other Ethnicity







#### **Methodology Note**

Data for Hispanic patients (and to lesser extent, Black and Other) is skewed to a bias in younger age groups, interpret w/caution.

#### Age 40-64:

White: 30%
Black: 58%
Hispanic: 73%
Asian/Pacific: 61%
Am. Indian/Aleut: 64%

# **DETAILED FINDINGS By Oncologist Gender**


# ONCs

# SUMMARY – ONCOLOGIST GENDER AND REGION: WHILE THERE ARE NOT MANY ATTITUDINAL DIFFERENCES BY GENDER, THERE ARE SOME REGIONAL DIFFERENCES

- Looking at attitudes across ONC gender, there are very few differences
  - Male and Female ONCs identify similar barriers to adopting complementary therapies
  - Most integrative attitudes are not significantly different
  - The one exception is survival female ONCs are significantly more likely to strongly agree that an integrative treatment approach is effective at improving overall survival
- Regionally, the West stands out as somewhat more favorable to integrative oncology, while South is the weakest
  - ONCs exhibit similar integrative oncology statement agreement across the four regions, with the West directionally higher than other regions
  - ONCs from the West have the integrative conversation with more patients than average and want to learn more about the evidence base for integrative oncology
  - Midwest and West ONCs cite lack of patient insurance reimbursement as the top barrier preventing the adoption of complementary therapies
  - ONCs from the Northeast, Midwest, and West offer most complementary therapies at their institutions at a directionally or significantly higher rate than Southern ONCs




# While statement agreement is similar between the two genders, female ONCs are significantly more likely to believe that an integrative treatment approach is effective at improving overall survival





### Male and Female ONCs identify similar barriers to adopting complementary therapies



Roughly a third of male ONCs feel there is not enough time to fit in conversations about complementary therapies

% of respondents did not see any barriers to further adoption of complementary therapies:

Male: 9% Female: 7%


\*Full list of barriers in speaker notes

79

# **DETAILED FINDINGS By Oncologist Region**




# ONCs exhibit similar integrative oncology beliefs across the four regions, with the West directionally higher than other regions






# ONCs from the Northeast, Midwest, and West offer most complementary therapies at their institutions at a directionally or significantly higher rate than Southern ONCs





# ONCs from the West have the integrative conversation with more patients than average and want to learn more about the evidence base for integrative oncology




#### **Supplemental Data**

% of cancer patients who discussed integrative treatments with their ONCs:

Northeast: 40% Midwest: 41% South: 38% West: 55% N,S



# Midwest and West ONCs cite lack of patient insurance reimbursement as the top barrier preventing the adoption of complementary therapies



## **APPENDIX**

# DEFINITION OF INTEGRATIVE ONCOLOGY PROVIDED TO RESPONDENTS (1 OF 2)

Therapy	Description
Nutrition Consultation or Program	A nutritional consult typically begins with a professional evaluation to assess the patient and the patient's diet. The nutritionist may also assess sleep patterns, physical activity, and other lifestyle factors. With this information, the nutritionist works with the patient (or client) to identify opportunities for change.
Exercise Consultation or Program	An exercise consultation typically involves a discussion with a physiologist who helps develop a plan for the patient that may include flexibility, strength and cardiovascular aspects. Exercise programs for cancer patients take into account the strain on the body during and after treatment and are tailored at the individual or group class level.
Acupuncture or Acupressure	Acupuncture is a practice in which a trained specialist called an acupuncturist stimulates, usually with a needle, a specific point on the skin called acupoints. The purpose of acupuncture is to rebalance or correct the body's energy flow, relieve pain and stimulate the body to heal itself.
Yoga Therapy	Yoga is a group of physical, mental, and spiritual practices that may combine physical postures, breathing techniques, and meditation or relaxation. In therapeutic yoga, traditional yoga postures are applied to treat chronic health conditions. Practitioners receive additional training in anatomy, physiology, psychology, and other medically related topics.
Massage Therapy	Massage therapy is a healing practice that is thousands of years old. It is the manual administration of pressure to the body's soft tissue including muscles, tendons, ligaments and connective tissue. Massage therapy is typically performed to loosen and relax tissue, but can also be performed to treat serious health issues, like chronic pain.
Spiritual Services	Spiritual services are the aspect of health care that attends to spiritual and religious needs of the patient; for example, speaking to a chaplain of your chosen faith

# DEFINITION OF INTEGRATIVE ONCOLOGY PROVIDED TO RESPONDENTS (2 OF 2)

Therapy	Description
Meditation or Mindfulness	Mindfulness is the basic human ability to be fully present, aware of where we are and what we're doing, and not overly reactive or overwhelmed by what's going on around us. Mindfulness meditation often uses breathing techniques (focus on the breath) to help us suspend judgment and unleash our natural curiosity about the workings of the mind, approaching our experience with warmth and kindness, to ourselves and others.
Mental Health Support/Therapy	Mental health support/therapy helps patients with the psychological aspects of the treatment and management of cancer; it combines elements of psychiatry, psychology, and medicine with special concern for the psychosocial needs of the patient and his or her family.
Patient Support Groups or Patient- Survivor Pairings	Support groups are a tool for patients to connect with other people coping with cancer. Many organizations offer "buddy programs" that match patients with a survivor of the same type of cancer. Through this relationship, patients receive-on-one support throughout their cancer treatment.
Tai Chi or Qi Gong	Tai Chi and Qigong are moving meditations that build balance, coordination, strength, and functional capacity. Both practices combine the use of slow and deliberate movements with meditation and breathing practice.
Reiki or Therapeutic/Healing Touch	Reiki or Therapeutic/Healing Touch are types of bioenergy medicine includes a number of different therapeutic interventions where a therapist helps to harness or manipulate a patient's subtle energy in order to help restore the body's balance and improve the body's ability to heal. Some of the most commonly used bioenergetic therapeutic interventions are Therapeutic Touch/Healing Touch, Reiki, and the laying-on- of-hands.
Music or Art Therapy	Music therapy is a clinical intervention that uses music within a therapeutic process to assist the patient in identifying and dealing with social, cognitive, emotion or physical concerns. Art therapy is a form of clinical intervention that uses art as the primary mode of expression and communication. The art therapist uses creativity to help achieve personal and treatment-related goals.

## PRICE SENSITIVITY METER (VAN WESTENDORP)



PSM is a technique that measures the <u>expected price level</u> of a product or brand from the <u>customer perspective</u>. In other words, it is based on <u>customers' perception</u> towards the product or brand.

#### **Survey Questions:**

The four questions were amended based on the specific context of purchasing the patient's top 1-5 complementary therapies monthly



At what monthly cost would you consider your top 1-5 complementary therapies to be **too expensive** and **would not consider** purchasing?



**Expensive** 

At what monthly cost would you consider your top 1-5 complementary therapies to be **getting expensive**, but you **would still consider** purchasing?




At what monthly cost would you consider your top 1-5 complementary therapies to be **on the cheap side**, but you **would still consider** purchasing?



At what monthly cost would you consider your top 1-5 complementary therapies to be **too cheap** that you **would not consider** purchasing?


## PRICE SENSITIVITY METER (VAN WESTENDORP) – OUTPUTS


In Van Westendorp analysis, responses to the four questions are charted cumulatively and the intersections used in a systematic way to define an acceptable price range and an optimal price point. Example:






## PATIENT DEMOGRAPHICS (1/3)








#### PATIENT DEMOGRAPHICS (2/3)







### PATIENT DEMOGRAPHICS (3/3)

- To understand the age skew within the Hispanic patient sample, below are universe vs. sample proportions
  - Hispanic patients are the most skewed, with a high proportion ages 40-64, and none in the 75+ category
  - The same bias appears to a lesser extent in all ethnic groups, other than White
- Data in this report shown for the individual ethnicities other than White should be interpreted with caution, as it is not representative of the age distribution within the ethnic population

Caucasian/White			African American/Black			Hispanic/Latino			Asian or Pacific Islander			Native American, Eskimo, or Aleut								
Age	15- 39	40- 64	65- 74	75+	15- 39	40- 64	65- 74	75+	15- 39	40- 64	65- 74	75+	15- 39	40- 64	65- 74	75+	15- 39	40- 64	65- 74	75+
Universe Proportion	4%	35%	32%	30%	5%	46%	30%	19%	10%	46%	25%	19%	7%	43%	27%	24%	7%	43%	29%	21%
Sample Proportion	4%	30%	44%	23%	8%	58%	22%	13%	10%	73%	18%	0%	4%	62%	24%	11%	8%	64%	18%	10%

Red font: delta = >50% of Universe base proportion (tested on Universe base of >5%)

• The same analysis was run for gender within ethnicity and sample proportions match almost exactly (within 1% for all cells, not shown)

#### Sources:

Age/ethnicity: https://seer.cancer.gov/statistics-

network/explorer/application.html?site=1&data\_type=9&graph\_type=2&compareBy=rate\_type&chk\_rate\_type\_1=1&chk\_rate\_type\_2=2&chk\_rate\_type\_3=3&sex=1&race=6&age\_range=1&hdn\_stage=101&advopt\_precision=1&advopt\_show\_count=on&hdn\_view=1&advopt\_display=1

#### **METHODOLOGY: KEY CONSIDERATIONS**

#### Study Design

- Pre-tests conducted to ensure overall respondent comprehension and data accuracy
- ✓ Recruitment designed to target a representative sample of US cancer patients and US Oncologists
- Survey flow and content adjusted for each target audience appropriately (i.e., Patients and Physicians)





#### **Survey Elements**

- ✓ Respondents (Oncologists and patients) took a 10–15-minute survey to assess their cancer treatment experiences and attitudes
- ✓ Some mirror questions were asked for both the segments to assess insights on similar parameters/trends like patient usage and ONCs perception of integrative treatment, benefits of the same, as well as patient interest in integrative treatment vs. ONC-reported institutional availability
- ✓ For the patient survey, we used FACT-7 scoring to assess the quality of life for each individual patient
- ✓ Questions about patient willingness to pay were also included to assess price sensitivity

#### Analysis

✓ Weighted sample to the specific populations of interest (US cancer patients and US Oncologists), using general census data to fill in when specific population data was not known



# DATA WEIGHTING WAS IMPLEMENTED TO REPRESENT US CANCER PATIENTS AS WELL AS ONCOLOGISTS

#### Specific Data Weighting Methodology & Sample Plan Outlined Below

- The **sample design** accounted for numerous target demographic variables to properly represent the US population:
  - Adult Patients with Cancer
  - Ethnicity: Caucasian, African American, Hispanic, Pacific Islander, Native American/Aleut/ Eskimo/ Other Ethnic background
  - · Location: Urban, Suburban, Rural
  - · Gender: Male, Female
  - Geography (Region): New England, Middle Atlantic, East North Central, West North Central, South Atlantic, East South Central, West South Central, Mountain, Pacific
  - Age: 18-34, 35-44, 45-54, 55-64, 65+

#### Oncologists

- Tumor Focus: Solid malignancies and Liquid malignancies
- · Geography (Region): Midwest, Northeast, South, West
- · Location: Urban, Suburban, Rural
- Age: <41, 41-63, 63+
- Sampling quotas were set to ensure the margin of error was reasonably low for all cross-demographic populations of interest
  - The total sample size is 1004 for patients and 152 for physicians (tested at 95% confidence level)
- For the final **RIM weighting**, population figures were compiled from the most recent US Census data (2017), Cancer Census Data (2019), ASCO (2022) and Internal IQVIA Brand Impact Data (2022)
  - The sample data are weighted to proportionally represent each demographic variable
  - RIM weighting (Random Iterative Method of Weighting) is a technique used to weight market research data to known targets (for e.g., Ethnicity, Location, Gender, Geography and Age for patients and Tumor Focus, Geography, Location as well as Age for physicians) which allows independent weighting of each variable and balances across the sample to create a single weighting factor for each respondent, which is then applied to all questions
  - In addition, the data are also projected to the population, so prevalence can be shown in both percentages and number of respondents

# QUOTA/WEIGHTING SUMMARY TABLE: PATIENT AND PHYSICIAN TRACKER

	Category	Notes			
	Ethnicity	Census for Cancer Patients; recruiting quotas are slightly different from cancer patient census based on analysis need			
Patient	Location (urban/suburban/rural)	US Census			
ati	Gender	Census for Cancer Patients			
<b>a</b>	Geography	9 regions, Census for Cancer Patients			
	Age	Census for Cancer Patients			
	Tumor Focus	BrandImpact Data			
ian	Geography	4 regions, US Census			
Physician	Location (urban/suburban/rural)	ASCO 2022 article (rural) + ASTRO article 2019 (suburban and urban)			
	Age	Physician Population Data			

## QUOTA/WEIGHTING SOURCES AND ASSUMPTION: PATIENT TRACKER (1/2)

		Reference Data	Assumptions and Sources		
Gender	Male	51% (510)	Cancer Census Statistics Data (2019):		
Ger	Female	49% (490)	https://gis.cdc.gov/Cancer/USCS/#/Demographics/		
	New England	6% (n=60)			
	Middle Atlantic	15% (n=150)			
	South Atlantic	23% (230)			
Geo	<b>East South Central</b>	7% (n=70)	C C C		
	<b>West South Central</b>	11% (n=110)	Cancer Census Statistics Data (2015-2019):  https://gis.cdc.gov/Cancer/USCS/#/CongressionalDistricts/		
	<b>East North Central</b>	12% (n=120)	nteps.//gis.ede.gov/ editect/ oses/ii/ editglessionalbistricts/		
	<b>West North Central</b>	5% (n=50)			
	Mountain	6% (n=60)			
	Pacific	15% (n=150)			
on	Urban	27% (270)	US HUD and Census (2017):		
Location	Suburban	52% (520)	https://www.huduser.gov/portal/pdredge/pdr-edge-frm-asst-sec- 080320.html#:~:text=According%20to%20data%20HUD%20and,describe%20th		
Lc	Rural	21% (210)	eir%20neighborhood%20as%20rural		

## QUOTA/WEIGHTING SOURCES AND ASSUMPTION: PATIENT TRACKER (2/2)

		Reference Data	A	Assumptions and Sources				
	18 – 34 years old	3% (n=30)						
	35 – 44 years old	4% (n=40)	Cancer Census Statistics Data (2019): https://gis.cdc.gov/Cancer/USCS/#/Demographics/					
Age	45 – 54 years old	11% (110)						
	55 – 64 years old	24% (n=240)	necessify sisted engolf current of occupants and mention					
	65 years and older	58% (n=580)						
	African American/Black	10% (n=100)	Quota (from Screener) 5% (n=50)					
	Asian or Pacific Islander	3% (n=30)	1% (n=10)	The Reference data is directly taken from the Cancer Census Data for year 2019; however, quotas were set based on				
Ethnicity	Caucasian/White	78% (n=780)	70-90% (n=700-900)	experience and budget. The minority %'s in census are slightly higher.				
**	Hispanic/Latino	8% (n=80)	10% (n=100)					
	Native American, Eskimo, or Aleut	10/ (n=10)	10/ /10	Cancer Census Statistics Data (2019): <a href="https://gis.cdc.gov/Cancer/USCS/#/Demographics/">https://gis.cdc.gov/Cancer/USCS/#/Demographics/</a>				
	Some other ethnic background	1% (n=10)	1% (n=10)	<u> </u>				

# FINAL SAMPLE – PATIENT TRACKER (1/2)

		Target Quota	Final Quota
Gender	Male	51% (510)	46% (n=461)
	Female	49% (490)	54% (n=543)
	New England	6% (n=60)	6% (n=64)
	Middle Atlantic	15% (n=150)	14% (n=142)
	South Atlantic	23% (230)	22% (n=222)
	East South Central	7% (n=70)	6% (n=58)
Geo	West South Central	11% (n=110)	9% (n=93)
	East North Central	12% (n=120)	14% (n=137)
	West North Central	5% (n=50)	6% (n=62)
	Mountain	6% (n=60)	7% (n=67)
	Pacific	15% (n=150)	16% (n=159)
uo	Urban	27% (270)	32% (n=319)
Location	Suburban	52% (520)	50% (n=500)
L L	Rural	21% (210)	18% (n=185)

## FINAL SAMPLE – PATIENT TRACKER (2/2)

		Target Quota	Final Quota	
	18 – 34 years old	3% (n=30)	8% (n=81)	
	35 – 44 years old	4% (n=40)	8% (n=85)	
Age	45 – 54 years old	11% (110)	15% (n=148)	
	55 – 64 years old	24% (n=240)	22% (n=218)	
	65 years and older	58% (n=580)	47% (n=472)	
	African American/Black	5% (n=50)	9% (n=92)	
	Asian or Pacific Islander	1% (n=10)	2% (n=24)	
icity	Caucasian/White	70-90% (n=700-900)	79% (n=797)	
Ethnicity	Hispanic/Latino	10% (n=100)	7% (n=74)	
	Native American, Eskimo, or Aleut	40( / 40)	20/ / 47)	
	Some other ethnic background	1% (n=10)	2% (n=17)	

## QUOTA/WEIGHTING SOURCES AND ASSUMPTION: PHYSICIAN TRACKER

		Reference Data	Assumptions and Sources
	Midwest	25% (n=37)	
Geo	Northeast	23% (n=34)	Source: https://ascopubs.org/doi/10.1200/JOP.18.00149 (Table 1)
Ö	South	33% (n=49)	<b>30dice.</b> <u>Inteps.//ascopubs.org/doi/10.1200/30P.18.00149</u> (Table 1)
	West	20% (n=30)	
	Rural	10% (n=15)	Sources and Assumption:  • Rural: according to JCO's 2022 statistics, rural is 10.5%  ( <a href="https://ascopubs.org/doi/full/10.1200/OP.22.00168">https://ascopubs.org/doi/full/10.1200/OP.22.00168</a> ). Most of the other
Location	Urban	48% (n=72)	<ul> <li>sources were below 10 (but from past years), so used 2022 data.</li> <li>Urban and Suburban: used 2019 data on radiation oncologists since very hard to find this (<a href="https://www.onclive.com/view/shortage-of-cancer-care-">https://www.onclive.com/view/shortage-of-cancer-care-</a></li> </ul>
	Suburban	42% (n=63)	<ul> <li>providers-in-rural-areas-affects-patient-outcomes)</li> <li>Check on urban/suburban split done with M3 panel (2022, not representative), which shows urban (56%) higher than sub-urban (38%)</li> </ul>
	<=40 years	14% (n=21)	Assumption: 41-63 years: 64.1% (Calculated by adding 13.9% and 22% and
Age	41-64 years	64% (n=96)	subtracting by 100%)
	64+ years	22% (n=33)	Source: https://ascopubs.org/doi/pdf/10.1200/OP.22.00168

### FINAL SAMPLE – PHYSICIAN TRACKER

		Target Quota	Final Quota
Tumor	Solid malignancies	65% (n=98)	81% (n=123)
	Liquid malignancies	35% (n=52) (Source: BrandImpact 2022)	19% (n=29)
	Midwest	25% (n=37)	20% (n=30)
Geo	Northeast	23% (n=34)	22% (n=33)
Ge Ge	South	33% (n=49)	37% (n=56)
	West	20% (n=30)	22% (n=33)
uo	Urban	48% (n=72)	51% (n=77)
Location	Suburban	42% (n=63)	42% (n=64)
lo	Rural	10% (n=15)	7% (n=11)
	<=40 years	14% (n=21)	25% (n=38)
Age	41-63 years	64% (n=96)	64% (n=98)
	64+ years	22% (n=33)	11% (n=16)